Cancer cell membrane biomimetic nanosystem for homologous targeted dual-mode imaging and combined therapy

Abstract

Hypothesis: The use of tumor cell membrane-camouflaged nanoparticles, specifically the multifunctional biomimetic core–shell nanosystem MPCONPs, can enhance the targeting ability and immune escape functionality of traditional chemotherapy, leading to more precise drug delivery and improved treatment outcomes. Experiments: Preparation of MPCONPs: Autologous tumor cell membrane (CM) fragments are collected and used to create a shell for the nanoparticles. A trypsin-sensitive cationic polylysine framework is synthesized and embedded with oxaliplatin (L-OHP) and Ce6-AuNDs (a singlet oxygen generator). The MPCONPs are formed by assembling these components. Findings: MPCONPs, as nanoparticles camouflaged with tumor CM, have enhanced cellular uptake in cancer cells and improved the efficacy of photodynamic therapy (PDT) and chemotherapy (CT). This offers great potential for their use as individualized therapeutic agents for clinical oncology treatment.